Last reviewed · How we verify
Matching placebo to dapagliflozin — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Matching placebo to dapagliflozin (Matching placebo to dapagliflozin) — Merck Sharp & Dohme LLC. This is a matching placebo control arm, not an active drug; it contains no pharmacologically active ingredient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Matching placebo to dapagliflozin TARGET | Matching placebo to dapagliflozin | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Matching placebo to dapagliflozin CI watch — RSS
- Matching placebo to dapagliflozin CI watch — Atom
- Matching placebo to dapagliflozin CI watch — JSON
- Matching placebo to dapagliflozin alone — RSS
Cite this brief
Drug Landscape (2026). Matching placebo to dapagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/matching-placebo-to-dapagliflozin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab